Kanausin Khapharco medicine for vomiting and nausea (2 blisters x 20 tablets)

Vascular disorders

Endocrine disorders during prolonged treatment with metoclopramid are related to hyperkemin (menstrual loss, lots of milk, large breasts in men).

The reactions that are related or often occur when high doses include: foreign towering disorders, muscle tone disorders or acute movement disorders, Parkinson's syndrome, restless standing, even after using a single dose, especially in children and young people: Drinking, reducing cognitive ability, confusion, hallucinations.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Digestive bleeding, mechanical obstruction, or puncture of the gastrointestinal tract due to drugs that increase bowel movement and can make the condition worse.

adrenal marrow or suspected adrenal hydrosta due to the risk of drama hypertension.

Caution when using

neurological disorders

There may be symptoms of alphabetical disorders, common in children and young people and/or when using high doses. These reactions usually occur in the early stages of drug use, some cases occur after a single dose. Should stop the drug as soon as there is a manifestation of the pagoda.

In most cases, these symptoms are completely lost after stopping the drug. However, in some cases, the medication is required to treat symptoms (benzodiazepin in children and/or anti -anti -cholinergic drugs for Parkinson's treatment in adults). The distance of the dose is at least 6 hours, including vomiting or do not use one dose to avoid the risk of overdose.

Prolonged treatment with metoclopramid can cause late movement disorders, many cases of non -recovery, especially in the elderly. Therefore, do not extend the treatment time for more than 3 months. It is necessary to stop taking the drug as soon as there are manifestations of late -clinical movement disorders. Malignant neuroleptic syndrome has been reported to Metoclopramid for use as well as coordinated with other sedatives. Patients need to stop drugs and take appropriate treatment as soon as they occur.

Methemoglobin blood

Some cases of blood methemoglobin may be associated with NADH cytochrome B5 Reductase deficiency.

cardiovascular disorders

Some cases of serious adverse reactions on the heart have been reported including circulatory depravity, serious slow heart rate, cardiac arrest and prolonged QT after methemoglobin injection, especially intravenous injection.

kidney failure or liver failure

Recommendations to reduce the dose in patients with serious liver or liver failure.

The ability to drive and operate machinery

Metoclopramid can cause drowsiness, dizziness, movement disorders, muscle disorders and can affect the vision and ability to drive as well as operate the drug users of the drug user.

Pregnancy

Many data on pregnant women (with over 1,000 output indicators) show that Metoclopramid does not cause teratogenic or toxicity to the fetus, so it can be used during pregnancy if necessary. Due to the pharmacological properties of Metoclopramid similar to other sedatives, the use of drugs at the end of pregnancy may cause a risk of extracurricular syndrome on the child. Therefore, avoid using metoclopramid at the end of pregnancy; In case of drug use, closely monitor the above manifestations.

The period of breastfeeding

metoclopramid is excreted in small amounts of breast milk, so breastfed babies are at risk of adverse drug reactions. Therefore, it is not recommended to use metoclopramid during breastfeeding. On breastfeeding women use metoclopramid, it is necessary to consider stopping the drug.

Interactive drug

Combining contraindications

Contraindicated Metoclopramide combination with levodopa or dopamine owners due to antagonism.

Coordination should be avoided

Alcohol can increase the central nerve inhibition effect of Metoclopramide.

Coordination should be considered

Because metoclopramid increases the peristalsis of the gastrointestinal tract, it can change the absorption of some drugs.

anti -cholinergic and morphine derivatives: anti -cholinergic drugs and morphine derivatives may have antagonistic images with metoclopramid about the effects on the gastrointestinal motility.

Central pain relievers (Morphin derivatives, anti -anxiety drugs, H1 anti -h1 anti -sedatives, antidepressants, barbiturates, clonidin and related drugs): The combination of central analgesic drugs and Metoclopramid may increase mental influence.

sedative: Metoclopramid can increase the effects of neuroleptics and cause percentage disorders.

Serotonergic drug system: Metoclopramid combination and serotonergic drugs such as Serotonin recovery (SSRI) medications may increase the risk of serotonin syndrome.

Digoxin: Metoclopramid can reduce the bioavailability of digoxin. When used in combination, plasma digoxin concentration should be closely monitored.

cyclosporin: Metoclopramid increases the bioavailability of cyclosporin (increasing CMAX to 46% and increasing exposure to 22%). When used in combination, plasma cyclosporin levels should be closely monitored. The consequences of this interaction are not clinically.

Strong CYP2D6 inhibitors: Strong CYP2D6 inhibitors such as fluoxetin and paroxetin increase the level of Metoclopramid exposure in patients. Although the clinical consequences of interactions are not well known, it is necessary to closely monitor patients to detect adverse reactions to research on the correlation of the drug, not to mix this drug with other drugs.